Trials / Completed
CompletedNCT03611751
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study With Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,020 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986165 | Specified dose on specified days |
| OTHER | Placebo | Specified dose on specified days |
| DRUG | Apremilast | Specified dose on specified days |
Timeline
- Start date
- 2018-07-26
- Primary completion
- 2020-11-29
- Completion
- 2020-11-30
- First posted
- 2018-08-02
- Last updated
- 2022-12-20
- Results posted
- 2022-12-20
Locations
205 sites across 16 countries: United States, Australia, Canada, Czechia, Finland, France, Germany, Hungary, Israel, Italy, New Zealand, Poland, Puerto Rico, Spain, Sweden, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03611751. Inclusion in this directory is not an endorsement.